Idorsia News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.04.25	The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension (GlobeNewswire)
09.04.25	US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement (GlobeNewswire)
27.03.25	Idorsia publishes its Annual Report 2024 (GlobeNewswire)
17.03.25	US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients (GlobeNewswire)
14.03.25	Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia (GlobeNewswire)
04.03.25	Idorsia announces financial results for 2024 (GlobeNewswire)
27.02.25	Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call (GlobeNewswire)
26.02.25	Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations (GlobeNewswire)
26.02.25	Idorsia and Viatris update their collaboration for selatogrel and cenerimod (GlobeNewswire)
26.02.25	Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties (GlobeNewswire)
25.02.25	Bondholders approve amended terms of the 2025 convertible bonds (GlobeNewswire)
12.02.25	Idorsia publishes the resolutions for the upcoming bondholder meeting (GlobeNewswire)
15.01.25	Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders (GlobeNewswire)
14.01.25	Idorsia publishes an invitation to a bondholder meeting (GlobeNewswire)
13.01.25	Idorsia to call for a bondholder meeting (GlobeNewswire)
20.12.24	Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan (GlobeNewswire)
27.11.24	Idorsia enters into exclusive negotiations for global rights to aprocitentan (GlobeNewswire)
11.11.24	Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions (GlobeNewswire)
29.10.24	Idorsia announces financial results for the first nine months of 2024 (GlobeNewswire)
16.10.24	New data on aprocitentan to be presented at the ASN Kidney Week 2024 (GlobeNewswire)
17.09.24	Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 (GlobeNewswire)
05.09.24	New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 (GlobeNewswire)
02.09.24	Amended terms of Idorsia’s 2024 convertible bonds become effective (GlobeNewswire)
25.07.24	Idorsia announces financial results for the first half 2024 (GlobeNewswire)
18.07.24	Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call (GlobeNewswire)
01.07.24	Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension (GlobeNewswire)
28.06.24	Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds (GlobeNewswire)
25.06.24	Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds (GlobeNewswire)
21.06.24	Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category (GlobeNewswire)
13.06.24	Idorsia holds its Annual General Meeting of Shareholders (GlobeNewswire)
03.06.24	New data with daridorexant to be presented at SLEEP 2024 (GlobeNewswire)
03.06.24	New data with daridorexant to be presented at SLEEP 2024 (GlobeNewswire)
31.05.24	Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 (GlobeNewswire)
31.05.24	Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 (GlobeNewswire)
23.05.24	Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
23.05.24	Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
21.05.24	Idorsia announces changes to Idorsia Executive Committee and Board of Directors (GlobeNewswire)
21.05.24	Idorsia announces changes to Idorsia Executive Committee and Board of Directors (GlobeNewswire)
21.05.24	Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor (GlobeNewswire)
21.05.24	Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor (GlobeNewswire)
21.05.24	Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value (GlobeNewswire)
21.05.24	Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value (GlobeNewswire)
14.05.24	Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call (GlobeNewswire)
14.05.24	Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call (GlobeNewswire)
06.05.24	Bondholders approve amended terms of the 2024 convertible bonds (GlobeNewswire)
06.05.24	Bondholders approve amended terms of the 2024 convertible bonds (GlobeNewswire)
01.05.24	Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond (GlobeNewswire)
01.05.24	Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond (GlobeNewswire)
26.04.24	JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension (GlobeNewswire)
26.04.24	JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	86.09	1.63 %	K V
Geberit	538.00	1.62 %	K V
Givaudan	3’714.00	1.25 %	K V
Swisscom	515.50	1.08 %	K V
Nestle	84.98	0.81 %	K V
Swiss Re	138.05	-0.83 %	K V
Sonova Hldg	231.60	-1.28 %	K V
Logitech Intl	56.94	-2.00 %	K V
ABB	40.27	-2.21 %	K V
Zurich Insur Gr	529.20	-5.30 %	K V

mehr

09.04.25		Idorsia-Aktie steigt: Idorsia erhält FDA-Zulassung für aktualisiertes Tryvio-Etikett
08.04.25		SPI-Wert Idorsia-Aktie: So viel Verlust hätte ein Idorsia-Investment von vor einem Jahr eingefahren
04.04.25		SPI aktuell: SPI zum Start leichter
27.03.25		SPI-Handel aktuell: SPI verliert zum Handelsende
27.03.25		Angespannte Stimmung in Zürich: SPI notiert am Mittag im Minus
25.03.25		SPI-Wert Idorsia-Aktie: So viel Verlust wäre bei einem Investment in Idorsia von vor 5 Jahren angefallen
18.03.25		Börse Zürich in Grün: So entwickelt sich der SPI nachmittags
18.03.25		SPI-Titel Idorsia-Aktie: So viel Verlust hätte ein Investment in Idorsia von vor 3 Jahren bedeutet

09.04.25

Idorsia-Aktie steigt: Idorsia erhält FDA-Zulassung für aktualisiertes Tryvio-Etikett

08.04.25

SPI-Wert Idorsia-Aktie: So viel Verlust hätte ein Idorsia-Investment von vor einem Jahr eingefahren

04.04.25

SPI aktuell: SPI zum Start leichter

27.03.25

SPI-Handel aktuell: SPI verliert zum Handelsende

27.03.25

Angespannte Stimmung in Zürich: SPI notiert am Mittag im Minus

25.03.25

SPI-Wert Idorsia-Aktie: So viel Verlust wäre bei einem Investment in Idorsia von vor 5 Jahren angefallen